This episode explores the approval of resmetirom for NASH, analysing its integration into clinical practice and patient eligibility. The experts also discuss the role of lifestyle interventions alongside resmetirom, the use of biomarkers for patient selection, treatment monitoring, and the expected landscape changes over the next five years.


  • Aleksander Krag (Moderator)
  • Naim Alkhouri (Faculty)
  • Sven Francque (Faculty)
  • Amalia Gastaldelli (Faculty)

Related episodes

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments